Remove 2019 Remove Immunity Remove Immunization
article thumbnail

US opioid activists argue against Sackler family immunity in Purdue Pharma deal

The Guardian - Pharmaceutical Industry

Under a court reorganization plan, Sackler family members who controlled the Oxycontin maker were granted immunity and did not have to declare personal bankruptcy in exchange for a $6bn settlement, paid out over 10 years, to a fund created to offset costs created by the opioid dependency crisis that has cost hundreds of thousands of lives.

article thumbnail

Should People With Immune Problems Get Third Vaccine Doses?

NY Times

France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like these are on their own.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Judge rejects Purdue opioid settlement over Sackler family immunity

pharmaphorum

The Sacklers said earlier they would exit the settlement deal if they were not granted immunity, and the judge in the bankruptcy court that accepted the deal – Robert Drain – said he did not want to jeopardise what was on offer by seeking further changes.

Immunity 102
article thumbnail

Purdue bankruptcy court hands immunity to Sackler family

pharmaphorum

A US federal judge has approved a bankruptcy settlement for Purdue Pharma that grants the Sackler family that owned the business immunity from any further civil lawsuits accusing them of contributing to opioid epidemic – to the consternation of campaigners.

article thumbnail

Vaccines Won’t Protect Millions of Patients With Weakened Immune Systems

NY Times

Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies.

article thumbnail

Vidofludimus calcium by Immunic for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

Pharmaceutical Technology

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

article thumbnail

Johnson & Johnson Will Test its Vaccine in Infants

NY Times

The company’s coming trials will also involve pregnant women and people whose immune systems are compromised.

Immunity 144